Addiction specialists' attitudes toward psychedelics: A National Survey
- 7 August 2023
- journal article
- research article
- Published by Wiley in The American Journal on Addictions
- Vol. 32 (6) , 606-609
Abstract
Background and Objectives: In recent years, there has been accelerating scientific and public interest in the use of psychedelics to treat mental health disorders. Our study's objective was to assess the attitudes of addiction specialists regarding therapeutic psychedelics.Methods: Our study utilized an anonymous online survey to assess the opinions of 145 addiction specialists regarding the therapeutic promise, potential risks, and legalization of psychedelics in the treatment of psychiatric illness and substance use disorders. Psychedelics were defined in the survey as inclusive of nonserotonergic hallucinogens such as ketamine or MDMA in addition to “classic” serotonergic psychedelics.Results: Most respondents expressed positive attitudes to the therapeutic use of psychedelics, but a sizeable minority expressed concern for their addictive potential. Familiarity with psychedelic scientific literature was the strongest positive predictor of belief in the therapeutic potential of psychedelics, while concern for addictive potential was the strongest negative predictor.Discussion and Conclusions: Participants overall expressed more positive attitudes to the therapeutic use of psychedelics than we had hypothesized. This may be attributable to the accelerating pace of psychedelics research in recent years. Given the strong influence of concern for addiction risk on attitudes, future study is warranted to explore the findings regarding these concerns. These findings may also represent an opportunity for improved education of physicians regarding the addictive potential, and relative risks/benefits of psychedelics.Scientific Significance: Though there have been several prior studies assessing psychiatrist and psychologist attitudes toward psychedelics, we are unaware of any specifically examining the opinions of addiction specialists.Keywords
This publication has 9 references indexed in Scilit:
- Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use DisorderJAMA Psychiatry, 2022
- Attitudes and Beliefs about the Therapeutic Use of Psychedelic Drugs among Psychologists in the United StatesJournal of Psychoactive Drugs, 2021
- Psychedelic Knowledge and Opinions in Psychiatrists at Two Professional Conferences: An Exploratory SurveyJournal of Psychoactive Drugs, 2021
- A Randomized, Double-Blind, Placebo Controlled Phase 3 Study Assessing Efficacy and Safety of MDMA-Assisted Therapy for the Treatment of Severe PTSDBiological Psychiatry, 2021
- Trial of Psilocybin versus Escitalopram for DepressionNew England Journal of Medicine, 2021
- Diversity, equity, and access in psychedelic medicineJournal of Psychedelic Studies, 2019
- Epidemiology of hallucinogen use in the U.S. results from the National epidemiologic survey on alcohol and related conditions IIIAddictive Behaviors, 2019
- A Survey of American Psychiatrists' Attitudes Toward Classic HallucinogensJournal of Nervous & Mental Disease, 2018
- Physician Attitudes Regarding the Prescription of Medical MarijuanaJournal of Addictive Diseases, 2005